Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSirinart Kumfuen_US
dc.contributor.authorSiriporn C. Chattipakornen_US
dc.contributor.authorNipon Chattipakornen_US
dc.description.abstractCopyright © 2017 Wolters Kluwer Health, Inc. All rights reserved. In patients with thalassemia, iron overload cardiomyopathy is a major cause of cardiac dysfunction and mortality. Despite many advances in the development of new iron chelating agents, heart failure still occurs in some patients and can lead to an increase in mortality rate. Recently, potential novel therapeutic strategies in the treatment of these patients have focused on L-type and T-type calcium channel blockers. These 2 channels have been reported as being the main routes for cardiac iron uptake under conditions of iron overload. In this review, the effects of these calcium channel blockers on both cardiac iron uptake and cardiac function under conditions of iron overload are discussed, and both consistent and inconsistent findings published in various studies are summarized and reviewed. Through this we hope to provide a greater insight into how future studies can most effectively use these drugs at the clinical trial stage.en_US
dc.subjectPharmacology, Toxicology and Pharmaceuticsen_US
dc.titleT-type and L-type calcium channel blockers for the treatment of cardiac iron overload: An updateen_US
article.title.sourcetitleJournal of Cardiovascular Pharmacologyen_US
article.volume70en_US Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.